

Andras Inotai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2712312/publications.pdf>

Version: 2024-02-01

31
papers

827
citations

623734

14
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

1218
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposal for capturing patient experience through extended value frameworks of health technologies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 936-947.	0.9	4
2	Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 42.	1.5	5
3	Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 57.	1.5	7
4	The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia. <i>Frontiers in Pharmacology</i> , 2021, 12, 795002.	3.5	5
5	Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 653-659.	1.4	8
6	Potential Cost-Savings From the Use of the Biosimilars in Slovakia. <i>Frontiers in Public Health</i> , 2020, 8, 431.	2.7	8
7	Barriers and facilitators of exploiting the potential of value-added medicines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 229-236.	1.4	7
8	Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2020, 11, 845.	3.5	8
9	The impact of implemented regulations on biosimilars in Slovakia. <i>Health Policy and Technology</i> , 2019, 8, 408-413.	2.5	3
10	Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 195-204.	1.4	92
11	How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? â€œthe good, the bad, and the ugly ways. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 627-632.	1.4	10
12	Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 105-113.	1.4	11
13	Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals â€œan application on improving tender decision making in Indonesia. <i>BMC Health Services Research</i> , 2018, 18, 1003.	2.2	23
14	Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. <i>BioMed Research International</i> , 2018, 1-9.	1.9	23
15	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. <i>Frontiers in Pharmacology</i> , 2018, 8, 942.	3.5	70
16	Guidance toward the implementation of multicriteria decision analysis framework in developing countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 585-592.	1.4	24
17	Drug Policy in Hungary. <i>Value in Health Regional Issues</i> , 2017, 13, 16-22.	1.2	14
18	Is there a reason for concern or is it just hype? â€œA systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 915-926.	3.1	38

#	ARTICLE	IF	CITATIONS
19	Overview on Patient Centricity in Cancer Care. <i>Frontiers in Pharmacology</i> , 2017, 8, 698.	3.5	13
20	Relationship Between Medication Adherence and Health-Related Quality of Life in Subjects With COPD: A Systematic Review. <i>Respiratory Care</i> , 2015, 60, 297-303.	1.6	47
21	Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. <i>Value in Health Regional Issues</i> , 2015, 7, 1-8.	1.2	6
22	Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. <i>Eating and Weight Disorders</i> , 2015, 20, 1-12.	2.5	110
23	Need for Multicriteria Evaluation of Generic Drug Policies. <i>Value in Health</i> , 2015, 18, 346-351.	0.3	35
24	Benefits of investment into modern medicines in Central and Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 71-79.	1.4	11
25	Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. <i>BMC Health Services Research</i> , 2012, 12, 332.	2.2	22
26	Modelling the burden of disease associated malnutrition. <i>E-SPEN Journal</i> , 2012, 7, e196-e204.	0.5	19
27	Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. <i>Rheumatology International</i> , 2012, 32, 963-969.	3.0	17
28	Determinants of NSAID choice in rheumatoid arthritis--a drug utilization study. <i>Acta Poloniae Pharmaceutica</i> , 2012, 69, 773-7.	0.1	1
29	Factors Associated with Medication Adherence in Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2011, 82, 328-334.	2.6	117
30	Trends in the non-steroidal anti-inflammatory drug market in six Central and Eastern European countries based on retail information. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 183-190.	1.9	55
31	Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 190-195.	0.5	7